Pfizer, which has a market valuation of about USD 180 billion, earlier this year failed in its USD 118 billion bid to buy British rival AstraZeneca. It has an opportunity to make a fresh run at its target from late November under British takeover rules.
US drugmaker Pfizer is to continue buying back stock, with the board authorising a new USD 11 billion share repurchase plan, deflating expectations that it will make a new bid for AstraZeneca.
Shares in AstraZeneca fell 1.2 percent by 0800 GMT on Friday following the news.
The largest American pharmaceuticals company, whose shares gained more than 1 percent after the announcement late on Thursday, said the move was in addition to the USD 1.3 billion remaining on its current share buyback programme.
Pfizer, which has a market valuation of about USD 180 billion, earlier this year failed in its USD 118 billion bid to buy British rival AstraZeneca. It has an opportunity to make a fresh run at its target from late November under British takeover rules.
Pfizer Chief Executive Ian Read has said the company is continuing to look at deals but investor hopes for a new bid have dwindled recently because of the introduction of new US tax rules.
The US government's tax proposals are designed to make it harder for American firms to shift their tax bases out of the country and into lower cost jurisdictions in Europe, as Pfizer would do by buying AstraZeneca.
The likelihood of Pfizer resuming its pursuit has also been diminished following the collapse of US drugmaker AbbVie's USD 55 billion plan to buy Dublin-based Shire, as a result of the new U.S. tax regulations.
But while investors may well view the big new share buyback as another blow to the idea of a Pfizer bid, ISI Group analyst Mark Schoenebaum cautioned against reading too much into it. "We cannot and should not necessarily make that read-across," he said in a note
Anda sedang membaca artikel tentang
Pfizer's $11 bn buyback plan deflates AstraZeneca bid
Dengan url
http://remajantigalau.blogspot.com/2014/10/pfizers-11-bn-buyback-plan-deflates.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Pfizer's $11 bn buyback plan deflates AstraZeneca bid
namun jangan lupa untuk meletakkan link
Pfizer's $11 bn buyback plan deflates AstraZeneca bid
sebagai sumbernya
0 komentar:
Posting Komentar